Elsevier

Experimental Cell Research

Volume 293, Issue 1, 1 February 2004, Pages 14-21
Experimental Cell Research

Cytoplasmic mislocalization of BRCA1 caused by cancer-associated mutations in the BRCT domain

https://doi.org/10.1016/j.yexcr.2003.09.027Get rights and content

Abstract

BRCA1 is inactivated by gene mutations in >50% of familial breast and ovarian cancers. BRCA1 is primarily a nuclear protein, although others previously reported cytoplasmic staining in breast tumor cells. In this study, we demonstrate the cytoplasmic mislocalization of BRCA1 caused by a subgroup of clinically relevant cancer mutations. We show that mutations that disrupt or delete the C-terminal BRCT domains, but not other regions of BRCA1, caused significant relocalization of BRCA1 from nucleus to cytoplasm. Two of the BRCT mutations tested (M1775R and Y1853X) are known to adversely affect BRCA1 protein folding and nuclear function. The BRCT mutations reduced BRCA1 nuclear import by a mechanism consistent with altered protein folding, as indicated by the restoration of nuclear staining by more extensive C-terminal deletions. Furthermore, we observed increased cytoplasmic staining of both the ectopic and endogenous forms of the BRCA1-5382insC mutant (deleted BRCT domain) in HCC1937 breast cancer cells. Unlike wild-type BRCA1, the BRCA1-5382insC mutant failed to form DNA damage-inducible foci when targeted to the nucleus by BARD1. We propose that BRCT mutations alter nuclear targeting of BRCA1, and that this may contribute to the inhibition of nuclear DNA repair and transcription function.

Introduction

The BRCA1 tumor suppressor gene is mutated in the germ-line of women who suffer a genetic predisposition to breast and ovarian cancer [1], [2]. BRCA1 mutations are found in approximately 50% of patients with inherited breast cancer, and up to 90% of families with breast and ovarian cancer susceptibility [1], [2]. The BRCA1 protein comprises 1863 amino acids [1], and has proposed roles in DNA repair, transcriptional activation, cell cycle regulation and apoptosis [3], [4], [5]. BRCA1 has two main types of protein interaction domains that are frequently targeted by genetic mutations: an N-terminal RING finger domain and two tandem BRCT domains at the C-terminal end. The RING domain mediates an enzymatic ubiquitin E3 ligase activity when BRCA1 forms a stable heterodimer with its binding partner, BARD1 [6], [7]. The C-terminal BRCT domains are thought to mediate the transcriptional activity of BRCA1 [8], [9]. As a tumor suppressor, inherited mutations affect certain vital functions of BRCA1. The most frequent published mutations occur within the BRCT domains and these have been reported to adversely affect BRCA1 nuclear functions including DNA repair [10], [11] and transcriptional activity [9], [12], [13].

Several years ago, Chen et al. [14] published controversial findings which claimed that BRCA1 was mislocalized almost exclusively to the cytoplasm in breast cancer tissues, but remained nuclear in normal tissue and in other cancer cell types. However, this finding was not validated by others [15], and it was later concluded that antibody specificity was the main problem, with most agreeing that BRCA1 in general displayed a “primarily” nuclear localization in different breast cancer cell lines and in histological breast tumor tissue slices [16]. Nonetheless, BRCA1 subcellular localization is well known to vary between nucleus and cytoplasm in both patient tumor samples [17], [18] and in breast cancer cell lines [19], [20]. Our laboratory recently discovered that BRCA1 is a nuclear-cytoplasmic shuttling protein, and that its nuclear localization is regulated by the combined action of nuclear localization (NLS; [21], [22]) and nuclear export signals (NES; Ref. [23]). In most cases, however, cellular and ectopically expressed BRCA1 are primarily nuclear due to nuclear import mediated by the two NLSs and interaction with the RING domain binding protein, BARD1, which can carry BRCA1 into the nucleus and trap it there by masking its nuclear export signal [20].

We decided to revisit the question of BRCA1 subcellular localization, and more specifically to determine whether any of the more commonly studied gene mutations affect BRCA1 localization by regulating nuclear import or export. We demonstrate that out of the ten mutations tested, only the five which target the BRCT domains altered BRCA1 localization, causing it to be excluded from the nucleus. This nuclear exclusion was not due to increased nuclear export, but to reduced nuclear import. Similar findings were observed for both the overexpressed and endogenous forms of the BRCT mutant, BRCA1(5382insC). Since the BARD-dependent import pathway [20] is still active for the BRCT mutants, their overall nuclear entry is reduced but not fully negated. Our new findings may explain some of the disparity in the literature concerning BRCA1 localization and movement.

Section snippets

BRCA1 mutations within the BRCT domain cause cytoplasmic mislocalization

To assess the impact of BRCA1 cancer mutations on subcellular localization, we first used PCR-based mutagenesis to create a series of single-site or truncated BRCA1 mutant cDNAs corresponding to naturally occurring breast and ovarian cancer-linked mutations [24], [25], [26], [27]. These mutant BRCA1 cDNAs were cloned into the mammalian expression vector, pFLAG-CMV2 (see Ref. [23]), for transfection and expression in human breast cancer cells. As summarized in Fig. 1, many of the BRCA1 mutations

Discussion

In this study, we identified a specific subset of C-terminal mutations (those localized to the BRCT domain) that cause the partial or near-complete nuclear exclusion of BRCA1. Similar findings were made for both transiently expressed and endogenous BRCA1. The observed cytoplasmic mislocalization may partly explain why BRCT mutations reduce BRCA1 nuclear DNA repair [10], [11], replication [27] and transcriptional activities [8], [9], [28], [29]. Significantly, even when the mutant

Acknowledgements

We thank Dr. Jeff Holt and Richard Baer for providing BRCA1 and BARD1 plasmids and antibodies. This work was supported in part by grants to BRH from the National Health and Medical Research Council of Australia and the CureCancer Australia Foundation.

References (40)

  • R. Scully et al.

    Dynamic changes of BRCA1 subcellular location and phosphorylation state are initiated by DNA damage

    Cell

    (1997)
  • Y. Miki et al.

    A strong candidate for the breast cancer susceptibility gene BRCA1

    Science

    (1994)
  • F.J. Couch et al.

    Mutations and polymorphisms in the familial early-onset breast cancer (BRCA1) gene. Breast Cancer Information Core

    Hum. Mutat.

    (1996)
  • Y. Chen et al.

    Emerging roles of BRCA1 in transcriptional regulation and DNA repair

    J. Cell Physiol.

    (1999)
  • R. Scully et al.

    In search of the tumour-suppressor functions of BRCA1 and BRCA2

    Nature

    (2000)
  • P.S. Brzovic et al.

    Binding and recognition in the assembly of an active BRCA1/BARD1 ubiquitin–ligase complex

    Proc. Natl. Acad. Sci. U. S. A.

    (2003)
  • M.S. Chapman et al.

    Transcriptional activation by BRCA1

    Nature

    (1996)
  • A.N.A. Monteiro et al.

    Evidence for a transcriptional activation function of BRCA1 C-terminal region

    Proc. Natl. Acad. Sci. U. S. A.

    (1996)
  • Q. Zhong et al.

    Association of BRCA1 with the hRAD50–hMRE11–p95 complex and the DNA damage response

    Science

    (1999)
  • F. Hayes et al.

    Functional assay for BRCA1: mutagenesis of the COOH-terminal region reveals critical residues for transcription activation

    Cancer Res.

    (2000)
  • Cited by (85)

    • The fellowship of the RING: BRCA1, its partner BARD1 and their liaison in DNA repair and cancer

      2022, Pharmacology and Therapeutics
      Citation Excerpt :

      Other mutations in the BRCA1 C-terminal, and particularly in the protein BRCT domain, were linked to its cytoplasmic localization. In their study, Rodriguez et al. reported that the relocalization of BRCA1 from nucleus to cytoplasm was caused exclusively by a subgroup of clinically relevant cancer mutations that disrupted or deleted the protein BRCT domains but no other regions of BRCA1 (Rodriguez, Au, & Henderson, 2004). In particular, five different BRCA1 constructs (Pro1749Arg, Met1775Arg, Tyr1853*, Gln1756fs and Δ1751) that contained single amino acid mutations or short deletions (including the removal of 11 amino acids within the C-terminal tandem BRCT domains in the Tyr1853* mutant) were seen to promote BRCA1 cytoplasmic mislocalization.

    • Overexpression of MLF1IP promotes colorectal cancer cell proliferation through BRCA1/AKT/p27 signaling pathway

      2022, Cellular Signalling
      Citation Excerpt :

      BRCA1 can be activated by phosphorylation [32], while promoter methylation is one of the accepted mechanisms for loss of function in BRCA1 [33]. The activity of BRCA1 is also modulated by post-translational modifications such as sumoylation or ubiquitylation [34]. Another way to regulate the BRCA1 activation is via transcriptionally activated [35].

    • BRCA1/P53: Two strengths in cancer chemoprevention

      2020, Biochimica et Biophysica Acta - Reviews on Cancer
    • BRCA1 mutation spectrum, functions, and therapeutic strategies: The story so far

      2018, Current Problems in Cancer
      Citation Excerpt :

      Loss of nuclear localization or export signals in truncated proteins due to mutations result in aberrant cellular localization of these proteins. This misplaced localization may result in novel protein-protein interactions.30 5677InsA insertion results in a frameshift mutation that translates truncated protein at codon 1853.31

    View all citing articles on Scopus
    1

    Present address: Department of Medical Oncology, Academic Hospital Vrije Universiteit Amsterdam, 1081HV, Amsterdam, The Netherlands.

    View full text